28194574|t|Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
28194574|a|Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size. Tolvaptan may be a useful treatment for severe neonatal PKD.
28194574	0	9	Tolvaptan	T103	UMLS:C1176308
28194574	10	19	treatment	T058	UMLS:C0087111
28194574	40	84	autosomal-dominant polycystic kidney disease	T017	UMLS:C0085413
28194574	101	145	autosomal-dominant polycystic kidney disease	T017	UMLS:C0085413
28194574	147	152	ADPKD	T017	UMLS:C0085413
28194574	187	200	recessive PKD	T017	UMLS:C0085548
28194574	202	210	Managing	T058	UMLS:C0376636
28194574	282	307	massive renal enlargement	T033	UMLS:C0542518
28194574	309	331	respiratory compromise	T033	UMLS:C4228652
28194574	336	349	hyponatraemia	T038	UMLS:C0877169
28194574	371	402	arginine vasopressin receptor 2	T103	UMLS:C3711287
28194574	403	413	antagonist	T103	UMLS:C0243076
28194574	414	423	tolvaptan	T103	UMLS:C1176308
28194574	439	452	hyponatraemia	T038	UMLS:C0877169
28194574	491	501	renal size	T201	UMLS:C0745522
28194574	503	512	Tolvaptan	T103	UMLS:C1176308
28194574	529	538	treatment	T058	UMLS:C0087111
28194574	559	562	PKD	T038	UMLS:C0022680